- Translate Bio (NASDAQ:TBIO) has priced an upsized initial public offering at $13/share, the midpoint of its range.
- It's selling 9.4M shares, bringing gross raise to $122.2M.
- It's expected to start trading on Nasdaq Global Market tomorrow.
- The company lists a number of major competitors in cystic fibrosis therapeutics, including Vertex Pharmaceuticals (NASDAQ:VRTX), Copernicus Therapeutics, Flatley Discovery Lab, Galapagos (NASDAQ:GLPG), Grifols (NASDAQ:GRFS), NovaBiotics, Novartis (NYSE:NVS), Novotersis, Parion Sciences, Proteostasis Therapeutics (NASDAQ:PTI), Protalix BioTherapeutics (NYSEMKT:PLX), Sanofi (NASDAQ:SNY), Spyryx Biosciences, and Verona Pharma (NASDAQ:VRNA).